Article
Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines.
International journal of clinical oncology - 1 Jun 2003
Omura Kenji
Abstract excerpt
Dihydropyrimidine dehydrogenase (DPD) is the rate-limiting enzyme in the degradation of pyrimidine bases. DPD is also responsible for the degradation of 5-fluorouracil (5-FU), which is the most frequently prescribed anticancer drug for the treatment of malignancies of the gastrointestinal tract. DPD could influence the antitumor effect and the adverse effects of 5-FU. High intratumoral DPD activity markedly...
Topics
- Antimetabolites, Antineoplastic
- Antineoplastic Combined Chemotherapy Protocols
- Clinical Trials as Topic
- Dihydrouracil Dehydrogenase (NADP)
- Fluorouracil
- Genetic Testing
- Humans
- Mutation
- Neoplasms
- Oxidoreductases
- Pharmacogenetics
- Pyridines
- Risk Assessment
- Sensitivity and Specificity
- Structure-Activity Relationship